During the blood clotting process, dspa inhibits factor x, which is an enzyme involved in the coagulation pathway. Draculin was first tested on humans in a 2006 study that found that the drug was not only safe, but patients also tolerated it If effective, draculin would help prevent ischemic strokes, a type of stroke caused when blood clots block blood flow to the brain. Draculin is a glycoprotein that irreversibly binds to factors ixa and x, and inhibits the conversion of prothrombin to thrombin [6, 7, 13] This prevents fibrinogen being converted into fibrin and thus inhibits coagulation of blood during feeding [5]. Vampire bats produce an anticoagulant called draculin (named for the famous monster) that helps them feed on blood without it clotting
Scientists are studying possible human uses for draculin, such as turning it into an anticlotting agent to prevent or treat strokes. Draculin is a reversible, slow tight binding, noncompetitive inhibitor of fxa It does not act on thrombin, trypsin or chymotrypsin and does not express fibrinolytic activity. Draculin (named after count dracula) is a glycoprotein found in the saliva of vampire bats It is composed of 411 amino acids It functions as an anticoagulant, inhibiting coagulation factors ix (ixa) and x (xa), thus keeping the blood of the bitten victim from clotting while the bat is drinking.
This protein was isolated from the saliva of vampire bats. Draculin (named after count dracula) is a glycoprotein found in the saliva of vampire bats. Draculin, a glycoprotein isolated from vampire bat (desmodus rotundus) saliva, is a natural anticoagulant which inhibits activated coagulation factors ix (ixa) and x (xa).
WATCH
